Compare Novo Nordisk A/S (NVO) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Open Text Corporation — how do they compare? Novo Nordisk A/S trades at $46.28 (market cap $207.85B), while Open Text Corporation trades at $23.91 (market cap $5.80B). The key difference: Novo Nordisk A/S is far larger — about 35.8× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.67%). Which is the better fit depends on your goals.
| NVO | OTEX | |
|---|---|---|
Market Cap | $207.85B | $5.80B |
Sector | Health | Technology |
52-Week High | $63.98 | $39.69 |
52-Week Low | $35.29 | $20.01 |
Enterprise Value | $222.55B | $10.81B |
Dividend Yield | 3.81% | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Open Text Corporation (OTEX) trades at $23.62, down 4.45% in the past 24 hours, with a bullish technical signal despite bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.23 exceeding expectations. Valuation metrics appear attractive with a P/E of 9.29 and EV/EBITDA of 5.95, while profitability remains solid with a net income margin of 12.26% and ROE of 16.19%.
The outlook is positive given consistent earnings outperformance and a consensus price target of $29.33, implying 24% upside. Risks include high debt levels and competitive pressures in the software sector. Investor sentiment is mixed, with analysts showing cautious optimism amid recent institutional selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
